The connection between poor sleep and cardiovascular disease just gained a compelling mechanistic explanation that could reshape how we approach both conditions. Rather than viewing sleep apnea as merely a breathing disorder that stresses the heart, new evidence reveals it fundamentally rewires gut bacteria to produce metabolites that directly accelerate arterial plaque formation.
Researchers exposed atherosclerosis-prone mice to intermittent oxygen deprivation mimicking sleep apnea for 10 weeks while feeding them a Western diet. The sleep disruption dramatically increased aortic plaque buildup, but this effect vanished completely in mice lacking the farnesoid X receptor (FXR), a bile acid sensor. The intermittent hypoxia shifted gut microbial populations toward species that modify bile acids, particularly increasing bacterial hydroxysteroid dehydrogenase enzymes. This microbial remodeling altered the bile acid pool composition, which then signaled through FXR to promote cardiovascular inflammation and plaque development.
This discovery bridges three seemingly separate health domains—sleep disorders, gut microbiome dysbiosis, and cardiovascular disease—through a unified molecular pathway. The FXR-bile acid axis represents a novel therapeutic target that could benefit the estimated 936 million adults worldwide with sleep apnea. Current treatments focus on mechanical airway support, but targeting microbial bile acid metabolism might offer complementary protection against the cardiovascular complications that make sleep apnea so dangerous. However, this mouse model used extreme dietary and oxygen conditions that may not fully reflect human sleep apnea pathophysiology. The findings suggest that optimizing gut microbial health through diet, probiotics, or bile acid modulators could potentially mitigate cardiovascular risks in sleep apnea patients, warranting clinical investigation of this gut-heart connection.